Roflumilast Altana Pharma

Curr Opin Investig Drugs. 2002 Aug;3(8):1165-70.

Abstract

Roflumilast is a specific PDE4 inhibitor being developed by Altana Pharma (formerly known as Byk Gulden) for the potential treatment of asthma and chronic obstructive pulmonary disease [312928].

Publication types

  • Review

MeSH terms

  • Aminopyridines / adverse effects
  • Aminopyridines / chemical synthesis
  • Aminopyridines / pharmacokinetics
  • Aminopyridines / pharmacology
  • Aminopyridines / therapeutic use*
  • Animals
  • Anti-Asthmatic Agents / adverse effects
  • Anti-Asthmatic Agents / chemical synthesis
  • Anti-Asthmatic Agents / pharmacokinetics
  • Anti-Asthmatic Agents / pharmacology
  • Anti-Asthmatic Agents / therapeutic use*
  • Benzamides / adverse effects
  • Benzamides / chemical synthesis
  • Benzamides / pharmacokinetics
  • Benzamides / pharmacology
  • Benzamides / therapeutic use*
  • Bronchoconstriction / drug effects
  • Bronchodilator Agents / adverse effects
  • Bronchodilator Agents / chemical synthesis
  • Bronchodilator Agents / pharmacokinetics
  • Bronchodilator Agents / pharmacology
  • Bronchodilator Agents / therapeutic use*
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Cyclopropanes
  • Humans
  • Leukocytes / drug effects
  • Leukocytes / enzymology
  • Phosphodiesterase Inhibitors / adverse effects
  • Phosphodiesterase Inhibitors / chemical synthesis
  • Phosphodiesterase Inhibitors / pharmacology
  • Phosphodiesterase Inhibitors / therapeutic use*
  • Structure-Activity Relationship

Substances

  • Aminopyridines
  • Anti-Asthmatic Agents
  • Benzamides
  • Bronchodilator Agents
  • Cyclopropanes
  • Phosphodiesterase Inhibitors
  • Roflumilast